BeOne Medicines Ltd.
ONC
$308.63
-$5.04-1.61%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 4.65B | 4.26B | 3.90B | 3.35B | 3.05B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.65B | 4.26B | 3.90B | 3.35B | 3.05B |
| Cost of Revenue | 1.20B | 1.10B | 1.06B | 1.00B | 912.73M |
| Gross Profit | 3.45B | 3.16B | 2.83B | 2.35B | 2.14B |
| SG&A Expenses | 2.00B | 1.91B | 1.87B | 1.75B | 1.63B |
| Depreciation & Amortization | -- | -- | -- | -- | -377.80K |
| Other Operating Expenses | 24.60K | 24.60K | 24.60K | 25.15M | 500.90K |
| Total Operating Expenses | 4.77B | 4.57B | 4.48B | 4.24B | 3.92B |
| Operating Income | -118.62M | -313.67M | -586.12M | -892.55M | -864.61M |
| Income Before Tax | -79.41M | -284.88M | -549.20M | -804.06M | -454.95M |
| Income Tax Expenses | 115.62M | 124.88M | 112.97M | 53.22M | 51.86M |
| Earnings from Continuing Operations | -195.03 | -409.75 | -662.17 | -857.27 | -506.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -195.03M | -409.75M | -662.17M | -857.27M | -506.81M |
| EBIT | -118.62M | -313.67M | -586.12M | -892.55M | -864.61M |
| EBITDA | 7.91M | -193.25M | -473.22M | -798.72M | -773.36M |
| EPS Basic | -24.31 | -50.58 | -82.04 | -106.77 | -63.43 |
| Normalized Basic EPS | -0.42 | -1.64 | -3.24 | -6.98 | -4.88 |
| EPS Diluted | -25.49 | -50.84 | -83.10 | -107.83 | -64.48 |
| Normalized Diluted EPS | -0.45 | -1.65 | -3.24 | -6.98 | -4.88 |
| Average Basic Shares Outstanding | 426.48M | 422.85M | 420.20M | 418.02M | 418.26M |
| Average Diluted Shares Outstanding | 33.46M | 32.85M | 32.32M | 32.15M | 32.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -7.43% | -3.54% | -2.19% | -1.69% | -3.07% |